Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;6(3):301-10.
doi: 10.1016/j.jare.2014.11.004. Epub 2014 Nov 27.

New era for management of chronic hepatitis C virus using direct antiviral agents: A review

Tamer Elbaz  1 , Mohamed El-Kassas  2 , Gamal Esmat  1
Affiliations
Review

New era for management of chronic hepatitis C virus using direct antiviral agents: A review

Tamer Elbaz et al. J Adv Res. 2015 May.

Abstract

The pegylated interferon regimen has long been the lone effective management of chronic hepatitis C with modest response. The first appearance of protease inhibitors included boceprevir and telaprevir. However, their efficacy was limited to genotype 1. Recently, direct antiviral agents opened the gate for a real effective management of HCV, certainly after FDA approval of some compounds that further paved the way for the appearance of enormous potent direct antiviral agents that may achieve successful eradication of HCV.

Keywords: Direct antiviral agents (DAA); HCV; Polymerase inhibitors; Protease inhibitors.

PubMed Disclaimer

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Different classes of direct antiviral agents (DAA).
Fig. 2
Fig. 2
Differences between the different DAA classes.
Fig. 3
Fig. 3
The different direct antiviral agent drugs.
None
See this image and copyright information in PMC

References

    1. Zeuzem S., Hezode C., Ferenci P., Dusheiko G.M., Alves K., Bengtsson L. Telaprevir in combination with peginterferon alfa-2a with or without ribavirin in the treatment of chronic hepatitis C. final results of the PROVE 2 study. Hepatology. 2008;48(1):418–419. - PubMed
    1. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–1850. - PubMed
    1. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827–1838. - PubMed
    1. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292–1303. - PubMed
    1. Kwo P.Y., Lawitz E.J., McCone J., Schiff E.R., Vierling J.M., Pound D. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. - PubMed

LinkOut - more resources